DK1460992T3 - Stabiliserede omvendte micellesammensætninger og anvendelser deraf - Google Patents
Stabiliserede omvendte micellesammensætninger og anvendelser derafInfo
- Publication number
- DK1460992T3 DK1460992T3 DK02797165T DK02797165T DK1460992T3 DK 1460992 T3 DK1460992 T3 DK 1460992T3 DK 02797165 T DK02797165 T DK 02797165T DK 02797165 T DK02797165 T DK 02797165T DK 1460992 T3 DK1460992 T3 DK 1460992T3
- Authority
- DK
- Denmark
- Prior art keywords
- mucosal
- hydrophilic
- compositions
- micelles
- water
- Prior art date
Links
- 239000000693 micelle Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 238000010521 absorption reaction Methods 0.000 abstract 2
- -1 vaccines Proteins 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 210000003892 absorptive cell Anatomy 0.000 abstract 1
- 239000008346 aqueous phase Substances 0.000 abstract 1
- 230000007248 cellular mechanism Effects 0.000 abstract 1
- 230000003413 degradative effect Effects 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 230000029087 digestion Effects 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000012071 phase Substances 0.000 abstract 1
- 239000002798 polar solvent Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0291—Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Birds (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33687301P | 2001-12-03 | 2001-12-03 | |
| US35477402P | 2002-02-05 | 2002-02-05 | |
| US37769102P | 2002-05-03 | 2002-05-03 | |
| PCT/US2002/038473 WO2003047493A2 (fr) | 2001-12-03 | 2002-12-03 | Compositions a base de micelles inverses et applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1460992T3 true DK1460992T3 (da) | 2009-06-22 |
Family
ID=27407158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02797165T DK1460992T3 (da) | 2001-12-03 | 2002-12-03 | Stabiliserede omvendte micellesammensætninger og anvendelser deraf |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8535650B2 (fr) |
| EP (1) | EP1460992B1 (fr) |
| JP (2) | JP2005515197A (fr) |
| AT (1) | ATE424815T1 (fr) |
| AU (1) | AU2002362039B2 (fr) |
| CA (1) | CA2468845C (fr) |
| DE (1) | DE60231549D1 (fr) |
| DK (1) | DK1460992T3 (fr) |
| WO (1) | WO2003047493A2 (fr) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US7083920B2 (en) * | 2001-05-18 | 2006-08-01 | Nagaoka & Co. Ltd. | Surface assembly for immobilizing DNA capture probes in genetic assays using enzymatic reactions to generate signal in optical bio-discs and methods relating thereto |
| US20050019901A1 (en) * | 2002-01-31 | 2005-01-27 | Evgenia Matveeva | Methods for synthesis of bio-active nanoparticles and nanocapsules for use in optical bio-disc assays and disc assembly including same |
| US8088734B2 (en) * | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
| US8236333B2 (en) * | 2005-10-19 | 2012-08-07 | Unirem, Inc. | Active agent delivery and/or odor retentive composition and methods of use thereof |
| US20090148929A1 (en) * | 2005-10-19 | 2009-06-11 | Unirem, Inc. | Biostimulation agent for bioremediation and methods therefor |
| ES2426445T3 (es) | 2006-04-07 | 2013-10-23 | Merrion Research Iii Limited | Forma de dosificación oral sólida que contiene un potenciador |
| JP5550338B2 (ja) | 2006-07-31 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | ペグ化持続型インスリン |
| EP2404934A1 (fr) | 2006-09-22 | 2012-01-11 | Novo Nordisk A/S | Analogues d'insuline résistants à la protéase |
| EP1961412A1 (fr) * | 2006-12-27 | 2008-08-27 | LEK Pharmaceuticals D.D. | Systèmes auto-microémulsifiants pour l'administration de médicaments |
| WO2008132224A2 (fr) | 2007-04-30 | 2008-11-06 | Novo Nordisk A/S | Procédé de déshydratation d'une composition de protéine, composition de protéine déshydratée et composition pharmaceutique contenant la protéine déshydratée |
| GB0713672D0 (en) * | 2007-07-13 | 2007-08-22 | Imp Innovations Ltd | Method for cell manipulation |
| US9260502B2 (en) | 2008-03-14 | 2016-02-16 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
| JP5749155B2 (ja) | 2008-03-18 | 2015-07-15 | ノボ・ノルデイスク・エー／エス | プロテアーゼ安定化アシル化インスリンアナログ |
| CN107096012A (zh) | 2008-05-07 | 2017-08-29 | 诺和诺德股份有限公司 | 肽的组合物及其制备方法 |
| CA2638240C (fr) | 2008-08-29 | 2010-02-02 | Alexander Macgregor | Methode de traitement des anomalies de la glycemie et des variations de la glycemie |
| US10098857B2 (en) * | 2008-10-10 | 2018-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds |
| US20100310660A1 (en) * | 2009-06-08 | 2010-12-09 | Taipei Medical University | Dry powder microparticles for pulmonary delivery |
| US8258250B2 (en) * | 2009-10-07 | 2012-09-04 | Johnson & Johnson Consumer Companies, Inc. | Compositions comprising superhydrophilic amphiphilic copolymers and methods of use thereof |
| US8399590B2 (en) * | 2009-10-07 | 2013-03-19 | Akzo Nobel Chemicals International B.V. | Superhydrophilic amphiphilic copolymers and processes for making the same |
| US11173106B2 (en) * | 2009-10-07 | 2021-11-16 | Johnson & Johnson Consumer Inc. | Compositions comprising a superhydrophilic amphiphilic copolymer and a micellar thickener |
| EP2542678B1 (fr) | 2010-03-04 | 2017-04-12 | InteRNA Technologies B.V. | Molécule de miarn définie par sa source et ses utilisations thérapeutiques pour cancers associés à l'emt |
| CA2792137C (fr) | 2010-03-24 | 2020-03-10 | Medesis Pharma | Systeme de micelle inverse comprenant des acides nucleiques et son utilisation |
| WO2011120033A1 (fr) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Compositions pharmaceutiques d'inhibiteurs de facteur xa sélectifs destinées à une administration orale |
| NZ605420A (en) | 2010-07-06 | 2015-02-27 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| US9724405B2 (en) * | 2010-11-05 | 2017-08-08 | Novavax, Inc. | Rabies glycoprotein virus-like particles (VLPS) |
| EP2661273A4 (fr) | 2011-01-07 | 2014-06-04 | Merrion Res Iii Ltd | Compositions pharmaceutiques de fer pour administration orale |
| EP2474617A1 (fr) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | MIR pour traiter une nouvelle angiogenèse |
| EP2671568A4 (fr) * | 2011-01-31 | 2015-06-03 | Maruho Kk | Composition dermique comprenant une micelle inverse polymère, et procédé de production de cette composition |
| AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
| KR101904824B1 (ko) * | 2011-09-06 | 2018-11-29 | 리쿠아비스타 비.브이. | 계면활성제 및 그것을 이용하여 전기 습윤 표시 장치를 제조하는 방법 |
| BR112014014213A2 (pt) * | 2011-12-12 | 2017-06-13 | Agratech Int Inc | agentes hemostáticos e método de utilização |
| WO2013095132A1 (fr) | 2011-12-22 | 2013-06-27 | Interna Technologies B.V. | Miarn pour le traitement du cancer de la tête et du cou |
| EP2836508B1 (fr) | 2012-04-11 | 2016-06-29 | Novo Nordisk A/S | Formulations à base d'insuline |
| KR102152751B1 (ko) * | 2012-09-28 | 2020-09-07 | (주)아모레퍼시픽 | 식물 유래 당단백질을 포함하는 마이크로캡슐 |
| EP3800256A1 (fr) | 2012-11-06 | 2021-04-07 | InteRNA Technologies B.V. | Combinaison à utiliser dans le cadre d'un usage thérapeutique contre des maladies ou des affections associées au mélanome ou à l'activation de la voie de signalisation braf |
| EP3055325B1 (fr) | 2013-10-07 | 2018-01-03 | Novo Nordisk A/S | Nouveau dérivé d'insuline |
| US10500289B2 (en) * | 2014-03-26 | 2019-12-10 | D. R. NANO Co., Ltd. | Method of using methylene blue nanoparticle for detecting cancer by bioimaging |
| US10034834B1 (en) * | 2014-10-24 | 2018-07-31 | Aqua Regenerative Therapies Llc | Compositions and methods for treating skin conditions |
| WO2016092569A1 (fr) | 2014-12-10 | 2016-06-16 | Council Of Scientific & Industrial Research | Composition micellaire inverse discontinue en phase fd3m cubique pour la libération prolongée de médicaments thérapeutiques |
| US10058490B2 (en) | 2014-12-24 | 2018-08-28 | L'oreal | Acoustically-activated cosmetic hydrogels |
| US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
| WO2016161200A1 (fr) | 2015-03-31 | 2016-10-06 | Uop Llc | Micro-émulsions de liquide ionique halométallate |
| WO2018109162A1 (fr) | 2016-12-16 | 2018-06-21 | Novo Nordisk A/S | Compositions pharmaceutiques contenant de l'insuline |
| JP2021501594A (ja) | 2017-11-03 | 2021-01-21 | インテアールエヌエー テクノロジーズ ビー．ヴイ．ＩｎｔｅＲＮＡ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． | ニューロンの欠損に関連する状態及び／又は疾患を処置及び／又は診断するため、或いはニューロンの再生／発生のための、ｍｉＲＮＡ分子、等価物、アンタゴミル、又はそれらの供給源 |
| US11185589B2 (en) * | 2019-04-11 | 2021-11-30 | R.P. Scherer Technologies, Llc | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability |
| WO2022216888A1 (fr) * | 2021-04-08 | 2022-10-13 | Enteris Biopharma, Inc. | Procédés de traitement de la puberté pédiatrique à l'aide de formulations orales de leuprolide |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61185332A (ja) * | 1985-02-12 | 1986-08-19 | Morinaga Milk Ind Co Ltd | 安定な油中水型乳化物およびその製造法 |
| DE3682257D1 (de) | 1985-11-22 | 1991-12-05 | Takeda Chemical Industries Ltd | Liposomzusammensetzung. |
| US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
| CA2015291C (fr) | 1989-04-27 | 1996-04-30 | Etsuo Hasegawa | Reticulum endoplasmique macromoleculaire |
| FR2659554B1 (fr) * | 1990-03-16 | 1994-09-30 | Oreal | Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant. |
| US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
| AU668509B2 (en) * | 1991-04-19 | 1996-05-09 | Affinity Biotech, Inc. | Convertible microemulsion formulations |
| AU2316892A (en) * | 1991-06-27 | 1993-01-25 | Emory University | Multiple emulsions and methods of preparation |
| DK0597007T3 (da) * | 1991-07-26 | 1996-11-18 | Smithkline Beecham Corp | V/O mikroemulsioner |
| JPH05194253A (ja) * | 1992-01-16 | 1993-08-03 | Kirin Brewery Co Ltd | 水溶性ポリペプチドホルモンを含む徐放性微小粒子状製剤及びその製造法 |
| GB9300875D0 (en) * | 1993-01-18 | 1993-03-10 | Ucb Sa | Nanocapsule containing pharmaceutical compositions |
| US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| WO1995003035A1 (fr) | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Liposomes polymerises presentant une stabilite amelioree et s'administrant oralement |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| DE69434626D1 (de) | 1993-11-17 | 2006-04-20 | Athena Neurosciences Inc | Transparente flüssigkeit zur verabreichung von verkapselten medikamenten |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| SE518619C2 (sv) * | 1994-12-09 | 2002-10-29 | Gs Dev Ab | Komposition för reglerad frisättning innehållande monokaproin |
| US5693516A (en) | 1995-11-27 | 1997-12-02 | Novo Nordisk Biotech, Inc. | Method for solubilizing proteins in organic solvents |
| US5985312A (en) | 1996-01-26 | 1999-11-16 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| PT839525E (pt) * | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
| US6417171B1 (en) * | 1997-01-23 | 2002-07-09 | Collaborative Laboratories, Inc. | Preparation of polymers by interfacial derivatization |
| IS4518A (is) * | 1997-07-09 | 1999-01-10 | Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group | Nýtt lyfjaform fyrir bóluefni |
| US6187335B1 (en) * | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| ATE327735T1 (de) * | 1998-04-01 | 2006-06-15 | Jagotec Ag | Taxan-mikroemulsionen |
| US20010025046A1 (en) * | 1999-06-24 | 2001-09-27 | Rong(Ron) Liu | Self-emulsifying systems containing anticancer medicament |
| US6673612B2 (en) | 1999-07-16 | 2004-01-06 | Mirus Corporation | Micellar systems |
| US6193997B1 (en) * | 1998-09-27 | 2001-02-27 | Generex Pharmaceuticals Inc. | Proteinic drug delivery system using membrane mimetics |
| US20030059376A1 (en) | 1999-06-04 | 2003-03-27 | Libbey Miles A. | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
| CA2375914A1 (fr) * | 1999-06-04 | 2000-12-14 | Delrx Pharmaceutical Corporation | Formulations comprenant des particules deshydratees d'agents pharmaceutiques et leur procede de preparation |
| GB0001928D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| EP1138310A1 (fr) * | 2000-03-28 | 2001-10-04 | Primacare S.A. | Proliposomes |
| JP2003535832A (ja) | 2000-06-09 | 2003-12-02 | ブリカス，テニ | ポリヌクレオチドおよび薬物の標的化リポソームへのカプセル化 |
| US20030113366A1 (en) | 2001-12-14 | 2003-06-19 | Macgregor Alexander | Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents |
| JP5194253B2 (ja) * | 2007-03-30 | 2013-05-08 | 国立大学法人弘前大学 | サケ軟骨に含まれるプロテオグリカンの新規な薬理用途 |
-
2002
- 2002-12-03 JP JP2003548757A patent/JP2005515197A/ja active Pending
- 2002-12-03 AU AU2002362039A patent/AU2002362039B2/en not_active Expired
- 2002-12-03 DK DK02797165T patent/DK1460992T3/da active
- 2002-12-03 CA CA2468845A patent/CA2468845C/fr not_active Expired - Lifetime
- 2002-12-03 WO PCT/US2002/038473 patent/WO2003047493A2/fr not_active Ceased
- 2002-12-03 EP EP02797165A patent/EP1460992B1/fr not_active Expired - Lifetime
- 2002-12-03 AT AT02797165T patent/ATE424815T1/de not_active IP Right Cessation
- 2002-12-03 DE DE60231549T patent/DE60231549D1/de not_active Expired - Lifetime
- 2002-12-03 US US10/497,775 patent/US8535650B2/en not_active Expired - Lifetime
-
2010
- 2010-08-06 JP JP2010177083A patent/JP5551540B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2468845C (fr) | 2011-08-23 |
| CA2468845A1 (fr) | 2003-06-12 |
| WO2003047493A3 (fr) | 2003-10-16 |
| WO2003047493A2 (fr) | 2003-06-12 |
| EP1460992A4 (fr) | 2008-05-21 |
| US8535650B2 (en) | 2013-09-17 |
| HK1071054A1 (en) | 2005-07-08 |
| JP2010280700A (ja) | 2010-12-16 |
| EP1460992A2 (fr) | 2004-09-29 |
| JP5551540B2 (ja) | 2014-07-16 |
| EP1460992B1 (fr) | 2009-03-11 |
| AU2002362039A1 (en) | 2003-06-17 |
| ATE424815T1 (de) | 2009-03-15 |
| US20050079145A1 (en) | 2005-04-14 |
| JP2005515197A (ja) | 2005-05-26 |
| DE60231549D1 (de) | 2009-04-23 |
| AU2002362039B2 (en) | 2007-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1460992T3 (da) | Stabiliserede omvendte micellesammensætninger og anvendelser deraf | |
| Fang et al. | Interactions of phospholipid bilayer with chitosan: effect of molecular weight and pH | |
| Shah et al. | Oral delivery of proteins: progress and prognostication | |
| WO2008058547A3 (fr) | Composition d'alpha-lactalbumine | |
| WO2002005829A3 (fr) | Procede permettant de reduire les changements dans la flore gastro-intestinale nuisibles du point de vue ecologique intervenus chez des patients suivant un traitement medicamenteux | |
| WO2003047494A3 (fr) | Compositions a base de micelles inverses stabilisees et applications | |
| WO2005112886A3 (fr) | Procedes et articles pour l’administration d’agents therapeutiques | |
| EP2471512A3 (fr) | Formulations des agents photosensibilisants non-polaires pour la thérapie photodynamique | |
| TR200500745T2 (tr) | Damar gelişimi inhibitörleri olarak kuinazolin türevleri. | |
| WO2002051390A3 (fr) | Nanoparticules lipidiques amphiphiles destinees a l'incorporation de peptides et/ou proteines | |
| JP2010502822A (ja) | ポリマー安定化リポソーム組成物および使用方法 | |
| AU2005288519A1 (en) | Fatty acid modified polylysines as antimicrobial agents | |
| AU2001264515A1 (en) | Melphalan derivatives and their use as cancer chemotherapeutic drugs | |
| CA3146115A1 (fr) | Formulation de film comprenant des porteuses | |
| ES2331264T3 (es) | Metodo para la sintesis de las sales de sodio de derivados retinoilo. | |
| WO2007061829A3 (fr) | Composition pharmaceutique | |
| Verekar et al. | Nanocochleates: revolutionizing lipid-based drug delivery with enhanced bioavailability, a review | |
| JP2004504409A5 (fr) | ||
| EP1173476A4 (fr) | Aliments fonctionnels a base de proteine de soja | |
| JP2009519211A5 (fr) | ||
| Yeole et al. | A review on nanocochleate–A novel lipid based drug delivery system | |
| KR20220045167A (ko) | 일반 의약품 및 의약품의 생체이용률을 증가시키는 방법 | |
| Vijeta et al. | Nanocochleate: as drug delivery vehicle | |
| WO2003092736A3 (fr) | Conjugues comportant des acides nucleiques peptidiques | |
| Zaheer et al. | Protein based nanomedicine: Promising therapeutic modalities against inflammatory disorders |